Results 161 to 170 of about 216,694 (240)

Reported Characteristics of Anaphylaxis Associated With Glatiramer Acetate: A Pharmacovigilance Analysis of the FDA and Canadian Databases

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT The FDA has mandated a Boxed Warning for glatiramer acetate (GA) due to the risk of serious anaphylactic reaction. This study aimed to characterize the reported features of GA‐associated anaphylaxis. Data mining was performed using the Reporting Odds Ratio (ROR) in the FDA Adverse Event Reporting System (FAERS) database (Q1 2004–Q1 2025) and ...
Tailei Nie, Hongyu Liu, Chuanxu Cheng, Jian Li, Jiajing Lu   +4 more
wiley   +1 more source

The role of fear of relapse in quality of life among patients with relapsing-remitting multiple sclerosis. [PDF]

Front Neurol
Öztürk P, Öztürk M.
europepmc   +1 more source

Safety and Effectiveness of Dimethyl Fumarate in Japanese Patients With Multiple Sclerosis: Subgroup Analysis of Older Patients and Patients Switching From Fingolimod or Natalizumab Using 2‐Year Post‐Marketing Surveillance Data

Clinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
In a 2‐year post‐marketing surveillance of Japanese patients with multiple sclerosis, dimethyl fumarate (DMF) showed manageable safety, with no new concerns identified; lymphocyte decreases were more frequent in older patients and those switching from fingolimod.
Ichiro Nakashima, Toshiyuki Fukazawa, Kazumasa Yokoyama, Takashi Yamamura, Hirofumi Ochi, Michihiro Kanda, Yayoi Sato, Ryusuke Sato, Haruki Makioka, Aya Tsuchiya, Takahiko Saida   +10 more
wiley   +1 more source

Health-Related Quality of Life in Radiologically Isolated Syndrome Resembles Relapsing-Remitting Multiple Sclerosis. [PDF]

J Clin Med
Benito-León J, Díez-Cirarda M, Ruiz-Ortiz M, Aladro Y, Cuevas C, Domingo-Santos Á, Galán Sánchez-Seco V, Labiano-Fontcuberta A, Gómez-López A, Salgado-Cámara P, Costa-Frossard L, Monreal E, Sainz de la Maza S, Matías-Guiu J, Montero-Escribano P, Martínez-Ginés ML, Ayuso-Peralta L, Matías-Guiu JA.   +17 more
europepmc   +1 more source

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Lancet Neurology, 2017
T. Kalincik, J. W. Brown, N. Robertson, M. Willis, Neil Scolding, C. Rice, A. Wilkins, O. Pearson, T. Ziemssen, M. Hutchinson, C. McGuigan, V. Jokubaitis, T. Spelman, D. Horáková, E. Havrdová, M. Trojano, G. Izquierdo, A. Lugaresi, A. Prat, M. Girard, P. Duquette, P. Grammond, R. Alroughani, E. Pucci, P. Sola, R. Hupperts, J. Lechner-Scott, M. Terzi, V. van Pesch, C. Rózsa, F. Grand'Maison, C. Boz, F. Granella, M. Slee, D. Spitaleri, J. Olascoaga, R. Bergamaschi, F. Verheul, S. Vucic, P. Mccombe, S. Hodgkinson, J. Sánchez-Menoyo, R. Ampapa, M. Simó, T. Csépány, C. Ramo, E. Cristiano, M. Barnett, H. Butzkueven, A. Coles   +49 more
semanticscholar   +1 more source

Bridging the Pregnancy Knowledge Gap: A Real‐World Analysis of Medication Use and Drug–Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The exclusion of pregnant individuals from clinical trials has resulted in a significant medical knowledge gap for this population. Leveraging real‐world data (RWD) provides a critical window into the prevalence and use of medications during pregnancy.
Jacqueline Williams, Rucha Sane, Amita Joshi, Kit Wun Kathy Cheung, Bianca Vora   +4 more
wiley   +1 more source

Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis. [PDF]

Front Immunol
Buhelt S, Hansen MB, Søndergaard HB, El Mahdaoui S, Hansen MM, Mahler MR, Romme Christensen J, Sellebjerg F.   +7 more
europepmc   +1 more source

Ventricular‐vascular coupling at rest and immediately following maximal exercise in adults with and without multiple sclerosis

Physiological Reports, Volume 14, Issue 15, August 2026.
Abstract Multiple sclerosis (MS) may impair ventricular‐vascular coupling (VVC), a measure of the interaction between the cardiac and vascular systems. We evaluated if VVC differed between individuals with and without MS with similar age‐predicted fitness.
Brooks A. Hibner, Natalia S. Lima, Sara R. Sherman, Robert W. Motl, Julio A. Chirinos, Shane Phillips, Philip S. Clifford, Anthony T. Reder, Tracy Baynard, Bo Fernhall   +9 more
wiley   +1 more source

Workplace difficulties in early-stage relapsing-remitting multiple sclerosis with low physical disability. [PDF]

Mult Scler J Exp Transl Clin
Pérez-Sempere Á, García-Arcelay E, Caruncho J, Candeliere-Merlicco A, Orviz A, Martín-Martínez J, Morales RP, Álvarez-Rodríguez E, Pacheco EM, Borrega L, Casanova I, Caminero AB, Sánchez-Menoyo JL, Gómez-Gutiérrez M, Carmona O, Calles C, Hernández MA, López-Muñoz P, González-Suárez I, Joly H, Maurino J.   +20 more
europepmc   +1 more source

The effect of cladribine tablets on intrathecal inflammation in relapsing-remitting multiple sclerosis. [PDF]

J Neuroinflammation
Marastoni D, Eccher C, Signori A, Anni D, Foschi M, Crescenzo F, Mazziotti V, Virla F, Sicchieri M, Turano E, Tamanti A, Camera V, Ziccardi S, Zanetti G, Pizzini FB, Martini S, Fratucello A, Bonetti B, Sormani MP, Calabrese M.   +19 more
europepmc   +1 more source